Yuying Tan Selected Research

Methionine (L-Methionine)

1/2021	Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.
11/2020	Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
5/2020	Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
3/2020	Oral Recombinant Methioninase Prevents Obesity in Mice on a High-fat Diet.
1/2020	The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
1/2020	Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
1/2019	Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
1/2019	Methioninase Gene Therapy.
1/2019	Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
1/2019	High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuying Tan Research Topics

Disease

51	Neoplasms (Cancer) 06/2022 - 08/2002
7	Melanoma (Melanoma, Malignant) 11/2020 - 10/2017
6	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2018
5	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2019
5	Colorectal Neoplasms (Colorectal Cancer) 03/2020 - 09/2019
4	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 01/2018
3	Colonic Neoplasms (Colon Cancer) 04/2022 - 12/2019
3	Neoplasm Metastasis (Metastasis) 11/2020 - 01/2018
3	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 01/2018
3	Anaphylaxis (Anaphylactic Shock) 01/2019 - 03/2004
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2019 - 05/2017
2	Inflammation (Inflammations) 02/2021 - 01/2019
2	Triple Negative Breast Neoplasms 11/2020 - 09/2020
2	Obesity 05/2020 - 03/2020
2	Synovial Sarcoma (Synovioma) 10/2018 - 04/2018
1	Chronic Obstructive Pulmonary Disease (COPD) 04/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	Hypoxia (Hypoxemia) 02/2021
1	Suppuration 02/2021
1	Wounds and Injuries (Trauma) 02/2021
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021
1	Non-alcoholic Fatty Liver Disease 05/2020
1	Liposarcoma 05/2020
1	Prostatic Neoplasms (Prostate Cancer) 05/2020
1	Starvation 03/2020
1	Lymphatic Metastasis 03/2020
1	Necrosis 09/2019
1	Fibrosarcoma 01/2019
1	Infections 01/2019
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2019
1	Body Weight (Weight, Body) 10/2018

Drug/Important Bio-Agent (IBA)

43	L-methionine gamma-lyaseIBA 01/2021 - 08/2002
31	Methionine (L-Methionine)FDA Link 01/2021 - 12/2003
9	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2020 - 09/2014
8	Pharmaceutical PreparationsIBA 01/2022 - 10/2017
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2019
6	Fluorouracil (Carac)FDA LinkGeneric 03/2020 - 09/2014
6	LyasesIBA 01/2019 - 07/2004
4	Temozolomide (Temodar)FDA LinkGeneric 03/2020 - 10/2017
4	EnzymesIBA 04/2010 - 12/2003
3	Gemcitabine FDA Link 01/2021 - 01/2018
2	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 01/2020
2	Leucovorin (Folinic Acid)FDA Link 03/2020 - 12/2019
2	pazopanib FDA Link 03/2020 - 03/2020
2	TrabectedinIBA 12/2019 - 11/2019
2	Caffeine (No Doz)FDA LinkGeneric 09/2019 - 10/2018
2	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2019 - 03/2004
2	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2016
2	Indicators and Reagents (Reagents)IBA 01/2016 - 09/2014
2	DNA (Deoxyribonucleic Acid)IBA 09/2014 - 08/2002
2	Amino Acids FDA Link 09/2008 - 12/2003
1	ChemokinesIBA 06/2022
1	Competitive Endogenous RNAIBA 04/2022
1	Long Noncoding RNAIBA 04/2022
1	Biological ProductsIBA 01/2022
1	NeuropeptidesIBA 02/2021
1	Oxygen (Dioxygen)IBA 02/2021
1	Substance PIBA 02/2021
1	RetinoidsIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	CycloleucineIBA 01/2021
1	Glutathione (Reduced Glutathione)IBA 01/2021
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2021
1	PlatinumIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	AntigensIBA 11/2020
1	LigandsIBA 11/2020
1	tigatuzumabIBA 11/2020
1	Insulin (Novolin)FDA Link 05/2020
1	LipidsIBA 03/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 03/2020
1	Decitabine FDA Link 01/2020
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2019
1	Selenomethionine (Sethotope)FDA Link 01/2019
1	Antineoplastic Agents (Antineoplastics)IBA 01/2019
1	methaneselenolIBA 01/2019
1	StaurosporineIBA 01/2019
1	CaspasesIBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2019
1	Cytochromes c (Cytochrome c)IBA 01/2019
1	VemurafenibIBA 01/2018
1	Tripartite Motif ProteinsIBA 09/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2016
1	Cisplatin (Platino)FDA LinkGeneric 09/2014
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 04/2010
1	Biomarkers (Surrogate Marker)IBA 09/2008

Therapy/Procedure

19	Therapeutics 01/2021 - 01/2005
10	Drug Therapy (Chemotherapy) 01/2021 - 08/2004
5	Aftercare (After-Treatment) 01/2021 - 01/2018
2	Injections 05/2020 - 01/2018
1	Immunotherapy 04/2022
1	Neoadjuvant Therapy 01/2021
1	Chemoradiotherapy 01/2021
1	Laparotomy 11/2020
1	Hair Removal (Depilation) 01/2019
1	Intraperitoneal Injections 01/2019
1	Laminectomy 01/2019
1	Oral Administration 01/2018